Crossing Death Valley: Bringing Neurotechnology to Psychiatric Clinics in Alberta, Canada

Abstract

Depression is a major public health problem, with a lifetime and 12-month prevalence estimated at 18 and 6% of adults. Depression is costly in terms of treatment and lost productivity and is the main burden of mental illness across the globe. Existing pharmacological and psychological treatments for depression result in clinically meaningful improvements in <60% of patients. An emerging treatment approach is non-invasive brain stimulation of depression-related brain targets through transcranial magnetic stimulation (TMS). In this perspective, we detail our efforts on bringing TMS to clinical populations in Alberta by utilizing a novel organizational structure that bridges the gap between academia and the health care system. The Addictions and Mental Health Strategic Clinical Network worked with stakeholders to (1) examine the evidence, (2) develop clinical tools for patient selection and protocol application, (3) create overall implementation and evaluation plans to aid in further scale and spread, and even (4) fund the purchase and deployment of devices. Through this work, five publicly supported clinics now exist in Alberta.

Interventional Psychiatry and Neurotechnologies: Education and Ethics Training

“…Although there are no population data available on rTMS utilization across Canada, the ability to access this Health Canada approved treatment varies by province as a function of whether it is publicly funded. While some provinces and territories provide funding for rTMS, 28 funding models vary with procedural fee codes available to any rTMS practitioners in Saskatchewan and Yukon, while there is restricted funding to specialty rTMS clinics in Nova Scotia, Quebec, and Alberta. Further advocacy is needed to ensure that funding for this treatment does not impede equitable access across the country.…”